Skip to main content
Premium Trial:

Request an Annual Quote

RBM, Correlogic Get $1.15M Grant to Develop Ovarian Cancer Biomarkers

NEW YORK (GenomeWeb News) — Rules-Based Medicine has won a grant from the National Cancer Institute to work with Correlogic Systems to develop biomarker panels for cancer detection, RBM said today.
The contract includes a Phase I fast-track component and a Phase II option that together amount to $1.15 million.
In the two phases of the project, RBM will develop and test quantitative multiplexed immunoassays that incorporate analytes that the two companies have identified as targets for use in ovarian cancer detection.
Correlogic also will expand its existing analytic platform to determine the value of incorporating 19 additional analytes into its assays. Meanwhile, RBM will add the 19 assays to its HumanMAP platform.
The two companies previously collaborated on making Correlogic’s OvaCheck diagnostic test for ovarian cancer.
"Our research will integrate additional biomarkers associated with ovarian cancer into the existing Correlogic panel with the aim of achieving sensitivity and specificity levels that can open this test to a wider population of women,” RBM CEO Craig Benson said in a statement.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.